CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Liquidia Technologies, Inc. - LQDA CFD

12.82
2.81%
Market Trading Hours* (UTC) Opens on Tuesday at 14:30

Tue - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.18
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023346 %
Charges from full value of position ($-4.44)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001124 %
Charges from full value of position ($0.21)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 12.47
Open 12.41
1-Year Change 0.49%
Day's Range 12.32 - 12.82
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 17, 2025 12.82 0.39 3.14% 12.43 12.89 12.29
Jan 16, 2025 12.47 0.28 2.30% 12.19 12.60 11.94
Jan 15, 2025 12.09 0.64 5.59% 11.45 12.27 11.37
Jan 14, 2025 11.33 -0.29 -2.50% 11.62 11.74 11.28
Jan 13, 2025 11.73 -0.14 -1.18% 11.87 11.97 11.50
Jan 10, 2025 12.15 -0.07 -0.57% 12.22 12.48 12.09
Jan 8, 2025 12.38 -0.08 -0.64% 12.46 12.55 12.19
Jan 7, 2025 12.29 0.31 2.59% 11.98 12.50 11.94
Jan 6, 2025 12.12 -0.11 -0.90% 12.23 12.29 12.02
Jan 3, 2025 12.22 0.28 2.35% 11.94 12.46 11.94
Jan 2, 2025 12.05 0.30 2.55% 11.75 12.16 11.72
Dec 31, 2024 11.71 0.30 2.63% 11.41 11.73 11.41
Dec 30, 2024 11.48 0.24 2.14% 11.24 11.65 11.21
Dec 27, 2024 11.48 -0.19 -1.63% 11.67 11.82 11.40
Dec 26, 2024 11.75 0.26 2.26% 11.49 11.87 11.25
Dec 24, 2024 11.51 0.17 1.50% 11.34 11.62 11.28
Dec 23, 2024 11.41 0.40 3.63% 11.01 11.42 10.86
Dec 20, 2024 11.03 0.50 4.75% 10.53 11.12 10.33
Dec 19, 2024 10.53 -0.06 -0.57% 10.59 10.80 10.33
Dec 18, 2024 10.68 -0.56 -4.98% 11.24 11.37 10.43

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Liquidia Technologies, Inc. Company profile

About Liquidia Corp

Liquidia Corporation is a biopharmaceutical company that is focused on the development, manufacturing and commercialization of products, which address unmet patient needs with a focus directed towards the treatment of pulmonary hypertension (PH). The Company operates, through its wholly owned subsidiaries, Liquidia Technologies and Liquidia PAH. Liquidia Technologies has developed YUTREPIA (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as generic treprostinil injection. Its United Therapeutics developed treprostinil under the brand name Remodulin. The Company’s PRINT engineering technology allows to engineer and manufacture uniform drug particles with control over the size, three-dimensional geometric shape and chemical composition of the particles. The Company operates from over 45,000 square foot facility in Morrisville, North Carolina.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Liquidia Corp revenues increased from $740K to $12.9M. Net loss decreased 42% to $34.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balanc decrease of 40% to $18.6M (expense), Depr of Fin Lease R/O Use Assets in SGA decrease of 80% to $267K (expense).

Industry: Pharmaceuticals (NEC)

419 Davis Drive, Suite 100
Suite
MORRISVILLE
NORTH CAROLINA 27560
US

People also watch

ETH/USD

3,294.27 Price
-5.220% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Gold

2,703.08 Price
-0.430% 1D Chg, %
Long position overnight fee 0.0056%
Short position overnight fee -0.0138%
Overnight fee time 22:00 (UTC)
Spread 0.60

BTC/USD

102,841.45 Price
-1.750% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

XRP/USD

3.10 Price
-5.720% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01547

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading